Webdisclosure.com

Search

APONTIS PHARMA AG APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share

Directive transparence : information réglementée

06/05/2021 20:09

DGAP-News: APONTIS PHARMA AG / Key word(s): IPO
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share

06.05.2021 / 20:09
The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share

  • Total placement volume of EUR 101 million including over-allotment and upsize options
  • Market capitalization post-money to total EUR 162 million based on placement price
  • Post-IPO free float expected to amount to 62% assuming greenshoe option exercised in full
  • First day of trading at Frankfurt Stock Exchange (Scale) scheduled for 11 May 2021 under ticker symbol APPH
 

Monheim am Rhein, 06 May 2021. APONTIS PHARMA AG ("APONTIS PHARMA" or "Company") a leading pharmaceutical company specializing in Single Pills in the German market, has set the placement price for its initial public offering ("IPO") at EUR 19.00 per share.

In total, 5,290,000 ordinary bearer shares with no par value were placed with investors in the IPO. The placement comprises 2,000,000 new shares from a capital increase against cash contributions, 1,600,000 secondary shares in a base deal and 1,000,000 secondary shares from the exercise of an upsize option by the major shareholder Paragon Partners as well as 690,000 secondary shares provided by Paragon Partners in connection with an over-allotment option, corresponding to a total placement volume of EUR 101 million.

Based on the placement price, APONTIS PHARMA's market capitalization amounts to EUR 162 million post-money. Upon completion of the IPO and assuming full exercise of the greenshoe option, the expected free float will amount to 62%, which will allow for liquid trading of the Company's shares.

The existing shareholders Paragon Partners and APONTIS PHARMA'S Management will continue to hold 31% and 7%, respectively, of the Company's shares following the placement.

APONTIS PHARMA intends to use the proceeds from the issuance of the new shares of EUR 38 million to primarily pursue selected investments in the development of new Single Pills, the acceleration of the development and licensing of its existing short-term product pipeline and the expansion of its marketing and sales activities to capture further market share as well as product acquisitions.

Karlheinz Gast, CEO of APONTIS PHARMA AG: "The strong support of investors for our business model is an important testimony to our Company, our employees and the chronically ill patients who are treated with our Single Pills. It fills us with great confidence and spurs us on to continue creating added value for our patients and employees as well as investors and our Company. We will use the funds raised to bring new Single Pills to market and expand our leadership position. In this way, we contribute to the wealth-building of our society and help prevent medically avoidable, premature deaths every day."

The first day of trading of APONTIS PHARMA's shares on the Frankfurt Stock Exchange (Scale) is scheduled for 11 May 2021 under the international securities identification number (ISIN) DE000A3CMGM5 and the ticker symbol APPH. Settlement with delivery of shares is expected to take place on 12 May 2021.

The purchaser offers submitted via the subscription functionality "DirectPlace(R)" of the Frankfurt Stock Exchange ("Subscription Functionality") were not allocated.

Preferential allocation to the Company's board members or their relatives, or to the Company's employees or business partners did not occur.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

About Paragon Partners GmbH:

Paragon Partners GmbH is one of the leading independent private equity firms in Europe with more than EUR 1.2 billion of equity under management. Paragon works closely with portfolio companies to achieve sustainable growth and operational excellence. The investment portfolio covers various industries and currently comprises 14 companies. Paragon was founded in 2004 and is based in Munich, Germany. For further information please refer to www.paragon.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA press contact

Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 03 30

IMPORTANT NOTICE

These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This publication constitutes neither an offer to sell nor a solicitation to buy securities of APONTIS PHARMA AG. The offer is being made solely by the means of, and on the basis of, the published securities prospectus (including any supplements thereto, if any). An investment decision regarding the publicly offered securities of APONTIS PHARMA AG should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge on the APONTIS PHARMA AG website.



06.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1193658

 
End of News DGAP News Service

1193658  06.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1193658&application_name=news&site_id=symex